Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Total Liabilities (2017 - 2025)

Historic Total Liabilities for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $296.9 million.

  • Sutro Biopharma's Total Liabilities fell 1282.57% to $296.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $296.9 million, marking a year-over-year decrease of 1282.57%. This contributed to the annual value of $342.6 million for FY2024, which is 670.19% up from last year.
  • According to the latest figures from Q3 2025, Sutro Biopharma's Total Liabilities is $296.9 million, which was down 1282.57% from $294.5 million recorded in Q2 2025.
  • Over the past 5 years, Sutro Biopharma's Total Liabilities peaked at $347.2 million during Q1 2025, and registered a low of $51.2 million during Q1 2021.
  • For the 5-year period, Sutro Biopharma's Total Liabilities averaged around $225.7 million, with its median value being $294.5 million (2025).
  • Per our database at Business Quant, Sutro Biopharma's Total Liabilities tumbled by 2869.48% in 2021 and then soared by 23767.21% in 2022.
  • Quarter analysis of 5 years shows Sutro Biopharma's Total Liabilities stood at $88.8 million in 2021, then skyrocketed by 113.74% to $189.9 million in 2022, then surged by 69.09% to $321.1 million in 2023, then grew by 6.7% to $342.6 million in 2024, then decreased by 13.33% to $296.9 million in 2025.
  • Its Total Liabilities stands at $296.9 million for Q3 2025, versus $294.5 million for Q2 2025 and $347.2 million for Q1 2025.